The effect of D-penicillamine on pulmonary findings in systemic sclerosis.

摘要: D-penicillamine has been used for the treatment of systemic sclerosis 2 decades. Forty-four patients who received a mean dose 636 mg 2.3 years and 48 untreated patients, had repeat pulmonary function tests performed after 3.5 4.8 years, respectively, were evaluated. There no significant changes in vital capacity or forced expiratory volumes during this time either group. However, diffusing carbon monoxide improved from 76% predicted to 87% D-penicillamine-treated patients. Untreated changed slightly, 73% predicted. When multiple logistic regression analysis was account factors which could have biased comparisons, improvement related use (P less than 0.05). This associated with further progression dyspnea fibrosis on chest radiograph, as well reduced skin thickening. These data suggest that may be useful involves lung; however, studies are needed.